How much passive income would a $10,000 investment in CSL shares generate?

Can this stock offer healthy dividends?

| More on:
A doctor in a white coat with a stethoscope around her neck holds her hands upwards as if to ask 'why' as she sits at her desk and looks at her computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Owners of CSL Ltd (ASX: CSL) shares have benefited from enormous capital growth over the past decade, powered by its excellent profit growth in that time. This profit generation is enabling larger and larger passive income payouts.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALL28 May 201428 May 2024Zoom ▾20152016201720182019202020212022202320242016201620182018202020202022202220242024www.fool.com.au

I like dividends because they allow investors to benefit from growth in the value of the business without having to sell shares to access that value.

CSL is one of the biggest companies on the ASX, with a market capitalisation of $135 billion. While it is a massive business, can it provide the same sort of dividend income as National Australia Bank Ltd (ASX: NAB), Westpac Banking Corp (ASX: WBC) or Rio Tinto Ltd (ASX: RIO)?

Let's look at how much passive income a $10,000 investment could generate with CSL shares.

Dividend potential of CSL shares

Dividends are paid for by the profit a company makes.

CSL's board decided to declare an FY23 final dividend of US$1.29 per share and a full-year dividend of US2.36 per share. Converted into Australian dollars, the total full-year dividend amounted to approximately A$3.59 per share, an increase of 13%. This came after the company generated net profit after tax (NPAT) of $2.19 billion in FY23.

The passive income growth continued in the FY24 first-half result, with the interim payout of US$1.19 per share. In Australian dollar terms, the half-year dividend was increased 12% to A$1.81.

The last two dividends paid by CSL amount to US$2.48 per share, or A$3.72 at the current exchange rate. That translates into a dividend yield of just 1.3%.

$10,000 investment

If I had $10,000 to invest in the ASX healthcare giant, I'd be able to buy 35 CSL shares.

Assuming CSL paid the same dividends over the next 12 months as the last 12 months, a shareholder would receive $130 of cash if they owned 35 CSL shares.

If its profit continues climbing, the company may be able to significantly increase its passive income in future financial years.

The broker UBS has forecast the company's dividend per share can increase to US$3.80 per share by FY28. If CSL did pay that amount, it would translate into a dividend yield of 2%, or around $200 in dollar terms.

While the prediction implies the CSL dividend could grow by more than 50% over the next four years, the dividend yield is still expected to be small by FY28.

CSL share price snapshot

Over the past year, the CSL share price has fallen more than 8%. According to UBS' profit projection, it's now trading at 30x FY24's estimated earnings.

Dividends may not be the most compelling reason to look at CSL shares, but its recovery from COVID-19 impacts and the product development pipeline could be more intriguing.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Health professional working on his laptop.
Earnings Results

2 ASX 300 healthcare shares making big moves on earnings updates

Let's see what these two shares reported on Thursday.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

2 ASX 200 pharmaceutical shares surging on big US news

Big news is getting investors excited on Wednesday. Let's find out what is happening.

Read more »

Bored man sitting at his desk with his laptop.
Healthcare Shares

The Cochlear share price hit a 52-week low last week, is it time to buy?

Is this an opportunity worth hearing about?

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Earnings Results

Cochlear share price sinks 10% on half-year result disappointment

Let's see why investors are hitting the sell button this morning.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

The CSL share price hit a 52-week low this week. Is it time to buy?

Is this beaten-up biotech a healthy opportunity?

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »